Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors Who Sold Allergan, Inc. Common Stock Between February 25, 2014 and April 21, 2014

BENSALEM, Pa.--(BUSINESS WIRE)--

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of persons who sold the common stock of Allergan, Inc. (“Allergan” or the “Company”) AGN between February 25, 2014 and April 21, 2014. The investigation concerns possible violations of federal securities laws. Investors who have losses of $100,000 or more are encouraged to contact the firm for more information.

The investigation is related to alleged violations of federal securities laws by Valeant Pharmaceuticals International, Inc. and Pershing Square Capital Management L.P., among others. Specifically, the investigation is related to allegations that Valeant unlawfully tipped Pershing Square about its plan to make a tender offer for Allergan, with Pershing Square then trading on non-public information by buying an approximately 9.7% stake in Allergan without first disclosing Valeant's plan to pursue a tender offer to acquire Allergan at a significant premium.

If you sold shares of Allergan stock between February 25, 2014 and April 21, 2014, and suffered losses of $100,000 or more, if you would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!